International Liver Cancer Association (ILCA) Avenue de Tervueren, 300 B-1150 Brussels Belgium info@ilca-online.org+32 (0)2 789 2345 +32 (0)2 743 1550 |
Speakers, Sessions, Symposia
Program At a Glance
|
|
General Session |
|
|
State-of-the-Art Lecture |
|
|
Symposium |
|
|
Special Lecture |
|
|
Workshop |
|
|
Industry Symposium |
| TIME |
Friday, 5 September |
| 11.30 - 12.30 |
Biocompatibles Symposium
The histological and clinical impact of the treatment of HCC patients eligible for surgery with intra arterial, doxorubicin Drug-Eluting Beads*
Lunch provided |
| 12.30 - 12.45 |
Session Break |
| 12.45 - 13.00 |
Opening Ceremony |
| 13.00 - 15.00 |
Risk factors in the pathogenesis of HCC
Chairs: Nelson Fausto (USA); Irene Ng (China)
- Identification of potential therapeutic targets in pre-clinical models of HCC
Speaker: Nelson Fausto (USA)
- Pathogenesis of HCV-induced HCC
Speaker: Jake Liang (USA)
- Pathogenesis of HBV-induced HCC
Speaker: Patrizia Paterlini-Bréchot (France)
- Chronic inflammation and altered SAMe methabolism in - NASH and alcohol-induced HCC
Speaker: José M. Mato (Spain) |
| 15.00 - 15.30 |
Coffee and Networking Break |
| 15.30 - 16.15 |
Clinical Lecture: Evidence-based outcomes in cancer research and HCC
Chair: Scott Friedman (USA)
Speaker: Barnett Kramer (USA) |
| 16.15 - 16.30 |
Session Break |
| 16.30 - 18.00 |
General Session 1: Treatment of HCC –Surgery and local ablation
Chairs: Jacques Belghiti (France)
Michael Abecassis, Chicago (USA)
O-001 Outcome following salvage liver transplant for recurrent hepatocellular carcinoma after resection: analysis of the OPTN database
Presenting author: Francis Yao
O-002 Partial liver resection for HCC in patients with good liver function can challenge liver transplantation
Presenting author: Jacques Belghiti
O-003 Outcome after curative resection for huge (10cm or more) hepatocellular carcinoma and prognostic significance of gross classification
Presenting author: Dai Hoon Han
O-004 Interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis – wonder or woe?
Presenting author: Stefan Breitenstein O-005 Predictive factors of distant recurrence and survival in 203 patients with cirrhosis child pugh a and hepatocellular carcinoma HCC (≤ 5cm) treated by radiofrequency ablation (RFA)
Presenting author: Gisèle G. N. Nkontchou
O-006 Treatment of malignant liver tumors with percutaneous microwave ablation: experience with complications in 1136 patients
Presenting author: Ping Liang |
| 18.00 - 18.15 |
Session Break |
| 18.15 - 19.15 |
Bayer Schering Pharma Symposium
Forging partnerships in the management of Hepatocellular Carcinoma:
multidisciplinary strategies to provide continuity of care* |
| 19.15 - 20.00 |
Welcome Reception | |
Back to top
| TIME |
Saturday, 6 September |
| 08.00 - 09.00 |
Sirtex Symposium
Expanding treatment options in HCC through Radioembolisation/SIRT* |
| 09.00 - 09.30 |
IARC perspective: New concepts in the epidemiology of HCC
Chair: Hashem El-Serag (USA)
Speaker: Paolo Boffetta (France) |
| 09.30 - 09.45 |
Session Break |
| 09.45 - 11.15 |
General Session 2: Molecular pathogenesis (genomics)
Chairs: Xin Wei Wang (USA)
Peter Galle (Germany)
O-007 Hepatocellular carcinoma with progenitor cell features: clinical and biological characterization
Presenting author: Pippa Newell
O-008 Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma
Presenting author: Yujin Hoshida
O-009 Transcriptional regulation of micro-RNAs highly expressed in human HCCs
Presenting author: Natalia Pediconi
O-010 miRNA-based molecular classification of hepatocellular carcinoma
Presenting author: Sara Toffanin
O-011 Molecular profiles in human nonalcoholic steatohepatitis (NASH) - related hepatocellular carcinoma (HCC) assessed by whole genome bioarray hybridization
Presenting author: Flair José Carrilho
O-012 In vivo reptin silencing blocks hepatocellular carcinoma progression
Presenting author: Jean Rosenbaum |
| 11.15 - 11.45 |
Coffee and Networking Break |
| 11.45 - 12.30 |
Translational Lecture: Molecular pathology and HCC: from cell of origin to diagnosis
Chair: Masamichi Kojiro (Japan)
Speaker: Pierre Bedossa (France) |
| 12.30 - 14.15 |
Poster Session and Lunch |
| 14.15 - 14.45 |
Forty years of research in HCC in South Africa
Chair: Morris Sherman (Canada)
Speaker: Michael Kew (South Africa) |
| 14.45 - 16.15 |
General Session 3: Clinical trials in molecular therapies
Chairs: Didier Samuel (France)
Al Benson (USA)
O-013 Phase 2 open-label study of brivanib alaninate in patients with hepatocellular carcinoma
Presenting author: Joong-Won Park
O-014 Determining the impact of macroscopic vascular invasion (MVI), extrahepatic spread (EHS), and ecog performance status (PS) on sorafenib safety and efficacy in patients with advanced hepatocellular carcinoma (HCC): sharp trial subset analyses
Presenting author: Jean-Luc Raoul
O-015 Randomized, phase I and pharmacokinetic (PK) study of RAD001, a mTOR inhibitor, in patients (PTS) with advanced hepatocellular carcinoma (HCC)
Presenting author: Li-Tzong Chen
O-016 Small molecule antagonists of beta-catenin/Tcf4 complex inhibit the growth of HCC cells in vitro and in vivo
Presenting author: Wei Wei
O-017 Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): analysis of correlations with outcome and tumor imaging parameters Presenting author: Sandrine J. Faivre O-018 A phase I clinical trial of prodrug-activating gene therapy for patients with hepatocellular carcinoma
Presenting author: Bruno Sangro |
| 16.15 - 16.45 |
Coffee and Networking Break |
| 16.45 - 18.15 |
General Session 4: Signaling and novel targets
Chairs: Gregory J. Gores (USA)
Sheng-Long Ye (P.R. China)
O-019 Transforming growth factor-beta gene expression signature predicts clinical outcome in cancer
Presenting author: Cedric COULOUARN
O-020 A gene signature enables to discriminate vascular invasion in patients with hepatocellular carcinoma
Presenting author: Beatriz Minguez
O-021 Identification of potential driver genes in hepatocellular carcinoma: mechanistic and clinical implications
Presenting author: Hyun Goo Woo
O-022 Bolstering hepatic cancer stem cells by Wnt/beta-catenin signaling
Presenting author: Xin Wei Wang
O-023 lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma
Presenting author: Lun-Xiu Qin O-024 Specific oncogenic pathways are activated in the different hepatocellular adenoma subtypes of tumors
Presenting author: Sandra Rebouissou |
| 18.15 - 18.45 |
Emerging molecules in HCC
Chair: Adrian M. Di Bisceglie (USA)
Speaker: Melanie Thomas (USA) |
| 18:45 - 21:15 |
ILCA-Workshop:
Liver transplantation in HCC
Entering the era beyond Milan and UCSF criteria in OLT
Building the future in solid ground
Organisation:
Pierre-Alain Clavien, Switzerland
Vincenzo Mazzaferro, Italy
Introduction: Goals, controversial data, goal of the workshop
Speaker: Pierre-Alain Clavien, Switzerland
Topic 1: Extension on what basis?
- Morphological parameters of HCC (size, number and volume of the tumor)
Chairs: Rafik M Ghobrial, USA, Myron Schwartz,USA
- UCSF / UCLA Criteria
Speaker: Francis Yao, USA
- Oriental Criteria
Speaker: Masatoshi Makuuchi, Japan
- Volume of the tumor
Speaker: Sven Jonas, Germany
- Biological markers and surrogates implying tumor sampling
Chairs: Snorri Thorgeirsson, USA, Kim Olthoff, USA
- Vascular invasion, Grading
Speaker: Eberhard Renner, Canada
- DNA ploidy implying serum markers, PIVKA
Speaker: Hiroto Egawa, Japan
Topic 2: Precising end-points in the extension process
Chairs: Josep Llovet, Spain/USA, Stefan Breitenstein, Switzerland
- Limitation of technology and modern approach of pre-transplant staging
Speaker: Riccardo Lencioni, Italy
- New model of prognostication: the “Metroticket caldulator”
Speaker: Vincenzo Mazzaferro, Italy
Topic 3: Should extended criteria be different between cadaveric and living donation?
Chairs: Jacques Belghiti, France and Jordi Bruix, Spain/USA
- YES
Speaker: Zakiyah Kadry, USA
- NO
Speaker: Michael Abecassis, USA
Topic 4: Influence of pre-transplant downstaging on post-transplant outcome and prognostication
Chairs: Pierre-Alain Clavien, Switzerland, Didier Samuel, France
- Pre-transplant downstaging
Speaker: Beat Müllhaupt, Switzerland Conclusion
Speaker: Vincenzo Mazzaferro, Italy | |
Back to top
| TIME |
Sunday, 7 September |
| 08.30 - 10.00 |
General Session 5: Epidemiology and molecular diagnosis
Chairs: Elizabeth M. Brunt (USA)
Young Nyun Park (Korea)
O-025 Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease - a national cohort study, 1978-2003
Presenting author: Rune Erichsen
O-026 Burden of hepatocellular cancer in a national sample of patients with chronic hepatitis C
Presenting author: Fasiha Kanwal
O-027 Occurrence of hepatitis C-related hepatocellular carcinoma (HCC) in the absence of cirrhosis: results from the HALT-C trial
Presenting author: Adrian M. Di Bisceglie
O-028 Hepatocellular carcinoma associated to chronic hepatitis delta
Presenting author: Raffaella Romeo
O-029 Telomere shortening, micronuclei, and inactivation of p21 during human multistep hepatocarcinogenesis
Presenting author: Young Nyun Park
O-030 Hepatocytic differentiation in cholangiocellular carcinoma suggesting hepatic progenitor cell origin
Presenting author: Mina Komuta |
| 10.00 - 10.30 |
Coffee and Networking Break |
| 10.30 - 12.30 |
Loco-regional treatments in HCC
Chairs: Luigi Bolondi (Italy)
Byung Ihn Choi (Korea)
- Local ablation: state-of-the art
Riccardo Lencioni (Italy)
- Chemoembolization: Eastern perspective
Kenichi Takayasu (Japan)
- Internal radiation: review of phase II data
Riad Salem (USA)
- Overview of evidence-based diagnosis and loco-regional management of HCC
Andrew Burroughs (UK) |
| 12.30 - 14.00 |
General Session 6 : Medical treatments
Chairs: Andrew Zhu (USA)
Kwang-Hyub Han (Korea)
O-031 A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma
Presenting author: Melanie B. Thomas
O-032 Efficacy and safety of sorafenib in asian patients with advanced hepatocellular carcinoma
Presenting author: Ann-Lii Cheng
O-033 Actual survival following chemoembolization for hepatocellular carcinoma in a US center: correlation with prognostic systems
Presenting author: Michael C. Soulen
O-034 Radiologic-pathologic correlation of treated HCC tumors with Y90 microspheres
Presenting author: Laura Kulik
O-035 Radioembolization with therasphere yttrium-90 glass microspheres for advanced hepatocellular carcinoma: a European pilot phase II study
Presenting author: Philip Hilgard
O-036 RE-188 Lipiodol therapy of hepatocellular carcinoma: results of a multinational study
Presenting author: Ajit K. Padhy |
| 14.00 |
Closing Remarks | |
* ILCA is not responsible for the topics and speaker selection of the industry symposium, nor of the opinions and statements producedat the time of their celebration.
Back to top |
Conference
Membership
ILCA – an International and Multi-disciplinary
Association for Liver Cancer Experts
Find out more about ILCA Member Benefits and how to become a member.
Association
Mission
The International Liver Cancer Association (ILCA) aspires towards advancing research in the pathogenesis, prevention, and treatment of liver cancer.
|
